COVID-19 vaccine development has been lightning-fast The vaccine is based on a modified common cold virus, which some experts warn could make it less effective than other vaccine efforts. Sinopharm recently built a second facility to manufacture the vaccine, doubling its capacity to about 200 million doses per year.ĬanSino Biologics (China): Set to begin large-scale human trials this summer, CanSino's vaccine has already been approved for the Chinese military. ![]() Early results suggest the drug is safe and at least somewhat effective. Sinopharm (China): Currently testing about 15,000 volunteers in the Middle East in a trial the state-owned company expects to last three to six months. Finally, read about how all of these issues and more weigh in on US President-elect Joseph Biden's plan to fight COVID-19. Testing is also key to slowing coronavirus' spread - learn about a device that can produce results in under 90 minutes here. Here's what we know so far about whether or not you can get COVID-19 more than once. Whether or not COVID-19 vaccines are effective at stopping the spread of coronavirus will depend a lot on how our bodies build immunity to the disease. However, health officials are very optimistic that the Pfizer vaccine and others like it could end the coronavirus pandemic. Statistically, only about 6% of vaccine candidates ever make it through to market, according to a Reuters report from April. While there are promising early results, there's no guarantee a vaccine will be ready by 2021. What to do until a coronavirus vaccine is approved?Ĭoronaviruses are a large class of viruses and so far there are no vaccines for any of them. So long as enough people take the vaccine to reach that level, it won't matter if a few people object or decline to take the vaccine for other reasons, for example, if they aren't healthy enough to be vaccinated. Life in the US will begin to return to normal once we reach what scientists call " herd immunity," which, with regard to the coronavirus, means at least 60% to 70% of the population is immune. For example, one vaccine for elderly or other high-risk patients, another for healthy adults and another for children. He also has said he foresees different vaccines being given to different patient populations. We probably won't know until next year, but Fauci has suggested we might require several different vaccines made and distributed by different labs to bring an end to the pandemic, in a paper published May 11 in the journal Science. Consumer spending seems to be trending upward as the prospect of a COVID-19 vaccine approaches, according to some economists.None of the volunteers who received Moderna's vaccine developed severe COVID-19 symptoms, according to an analysis by the peer-reviewed journal Science.Anthony Fauci predicts a "surge upon a surge" of COVID-19 infections in coming weeks, with the nation's top infectious disease expert pinning much of the blame on people gathering for the holidays. The US is averaging over 157,000 new cases of COVID-19 per day, based on a seven-day average.Cases of Pfizer's vaccine have started shipping across the US, with the first shipment delivered to Chicago late last week. ![]() The UK has become the first country in the world to authorize a rigorously-tested coronavirus vaccine, British Health Secretary Matt Hancock has announced. ![]() ![]() Sarah Tew/CNET Important COVID-19 vaccine news Until a vaccine arrives, coronavirus cases are expected to surge.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |